SCHEMBL716773

SCHEMBL716773

CC(C(=O)O)n1nc(-c2ccc(Cl)cc2)n(C=CC(F)(F)F)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
CNR1 P21554 2/20 0.35
ALDH1A1 P00352 1/20 0.34
AVPR2 P30518 3/20 0.33
AVPR1A P37288 3/20 0.33
KMT2A Q03164 3/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
TYMP P19971 1/20 0.32
PPP1CA P62136 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
ATM Q13315 1/20 0.32
P2RX3 P56373 2/20 0.32
PRCP P42785 1/20 0.32
RXRA P19793 1/20 0.32
NR4A2 P43354 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716772 1.00 KDM4E (0.35) KDM4ECNR1ALDH1A1AVPR2AVPR1A
SCHEMBL256747 0.78 AVPR2 (0.42) CNR1ALDH1A1AVPR2AVPR1A
SCHEMBL719971 0.78 AVPR2 (0.42) CNR1ALDH1A1AVPR2AVPR1A
SCHEMBL409585 0.76 AVPR2 (0.47) KDM4ECNR1AVPR2AVPR1A
SCHEMBL4502826 0.75 ALDH1A1 (0.43) KDM4ECNR1ALDH1A1AVPR2AVPR1A
SCHEMBL719977 0.75 AVPR2 (0.54) AVPR2AVPR1A
SCHEMBL717597 0.75 AVPR2 (0.54) AVPR2AVPR1A
SCHEMBL716223 0.75 AVPR2 (0.54) AVPR2AVPR1A
SCHEMBL4507074 0.74 CNR1 (0.39) KDM4ECNR1ALDH1A1AVPR2AVPR1A
SCHEMBL4498779 0.72 KDM4E (0.38) KDM4ECNR1ALDH1A1AVPR2AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034855-B2 Substituted phenylacetate and phenylpropane amides and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-19 US disclosed
US-20130231313-A1 SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-05 US disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231313-A1 SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF AADAC, NAT1, DNPEP KDM4E 2123/4885CNR1 3093/4885ALDH1A1 409/4885
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY AVPR2, AVPR1B, AVPR1A KDM4E 4683/4885CNR1 1028/4885ALDH1A1 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.